208465-72-9

Basic information

• Product Name: METHYL (2-CHLOROMETHYL)OXAZOLE-4-CARBOXYLATE
• Synonyms: METHYL 2-(CHLOROMETHYL)-1,3-OXAZOLE-4-CARBOXYLATE;METHYL (2-CHLOROMETHYL)OXAZOLE-4-CARBOXYLATE;METHYL 2-CHLOROMETHYL-4-OXAZOLECARBOXYLATE;2-CHLOROMETHYL-OXAZOLE-4-CARBOXYLIC ACID METHYL ESTER;Methyl 2-(chloromethyl)-1,3-oxazole-4-carboxylate 97%;4-Oxazolecarboxylic acid, 2-(chloroMethyl)-, Methyl ester;2-(Chloromethyl)-4-(methoxycarbonyl)-1,3-oxazole;Methyl2-(chloromethyl)-1,3-oxazole-4-carboxylate97%
• CAS NO: 208465-72-9
• Molecular Formula: C₆H₆ClNO₃
• Molecular Weight: 175.57
• Product Categories: pharmacetical;Building Blocks;Oxazole
• Mol File: 208465-72-9.mol
• Article Data: 16

Chemical Properties

• Melting Point: 74 °C
• Boiling Point: 230℃
• Flash Point: 93℃
• Appearance: /
• Density: 1.339
• Vapor Pressure: 0.0686mmHg at 25°C
• Refractive Index: 1.494
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -2.41±0.10(Predicted)
• CAS DataBase Reference: METHYL (2-CHLOROMETHYL)OXAZOLE-4-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL (2-CHLOROMETHYL)OXAZOLE-4-CARBOXYLATE(208465-72-9)
• EPA Substance Registry System: METHYL (2-CHLOROMETHYL)OXAZOLE-4-CARBOXYLATE(208465-72-9)

Safety Data

• Hazard Codes: C
• Statements: 34
• Safety Statements: 22-26-36/37/39-45
• Hazardous Substances Data: 208465-72-9(Hazardous Substances Data)

Usage

General Description

Methyl (2-chloromethyl)oxazole-4-carboxylate is a synthetic chemical compound with the molecular formula C6H6ClNO3. It is commonly used as an intermediate in the production of pharmaceuticals, agrochemicals, and other organic compounds. METHYL (2-CHLOROMETHYL)OXAZOLE-4-CARBOXYLATE is derived from oxazoles, which are important building blocks in organic synthesis. Methyl (2-chloromethyl)oxazole-4-carboxylate is known for its versatility and stability, making it a valuable tool in chemical research and development. Additionally, its chloromethyl group makes it a useful reagent for a variety of chemical transformations and reactions.

InChI:InChI=1/C6H6ClNO3/c1-10-6(9)4-3-11-5(2-7)8-4/h3H,2H2,1H3

Upstream product

• 175551-77-6 methyl 2-(bromomethyl)oxazole-4-carboxylate 
• 289030-37-1 2-dichloromethyl-4,5-dihydrooxazole-4-carboxylic acid methyl ester 
• 866324-08-5 methyl 2-(dichloromethyl)-1,3-oxazole-4-carboxylate 
• 124-41-4 sodium methylate 
• 3018-12-0 dichloroacetonitrile 
• 5680-80-8 methyl (2S)-2-amino-3-hydroxypropanoate hydrochloride 

Downstream Products

• 208465-67-2 2-iodomethyloxazole-4-carboxylic acid methyl ester 
• 866324-13-2 2-[(4R,6R,7E)-4,6-bis(tert-butyldimethylsilyloxy)-2-oxo-8-phenyl-7-octenyl]oxazole-4-carboxylic acid methyl ester 
• 391208-72-3 (4R),(6R)-6-(2-chloromethyloxazol-4-yl)-6-hydroxy-4-tert-butyldiphenylsilanyloxyhex-1-ene 
• 391208-71-2 (4R),(6R)-6-(2-chloromethyloxazol-4-yl)-6-tert-butyldimethylsilanyloxy-4-tert-butyldiphenylsilanyloxyhex-1-ene 
• 391208-74-5 (1R,3R)-3-(tert-butyldiphenylsilanyloxy)-1-(2-((E)-3-((2R,3S,4S,5S,6R)-3,5-dimethyl-6-((E)-2-(2-methyloxazol-4-yl)prop-1-en-2-yl)-4-(triisopropylsilanyloxy)tetrahydro-2H-pyran-2-yl)prop-1-enyl)oxazol-4-yl)hex-5-en-1-ol 
• 208465-60-5 (R)-((3R,4R,E)-7-((S,2E,4E)-6-(tert-butyldiphenylsilyloxy)-4-methyl-8-oxoocta-2,4-dienylamino)-2,4-dimethyl-7-oxohept-5-en-3-yl) 1-(2-(iodomethyl)oxazole-4-carbonyl)pyrrolidine-2-carboxylate 
• 208465-70-7 (R)-((3R,4R,E)-7-((S,2E,4E)-6-(tert-butyldiphenylsilyloxy)-8-hydroxy-4-methylocta-2,4-dienylamino)-2,4-dimethyl-7-oxohept-5-en-3-yl) 1-(2-(chloromethyl)oxazole-4-carbonyl)pyrrolidine-2-carboxylate 
• 208465-71-8 (R)-1-(2-Iodomethyl-oxazole-4-carbonyl)-pyrrolidine-2-carboxylic acid (E)-(1R,2R)-4-[(2E,4E)-(S)-6-(tert-butyl-diphenyl-silanyloxy)-8-hydroxy-4-methyl-octa-2,4-dienylcarbamoyl]-1-isopropyl-2-methyl-but-3-enyl ester 
• 208465-69-4 (R)-((3R,4R,E)-7-((S,2E,4E)-8-(tert-butyldimethylsilyloxy)-6-(tert-butyldiphenylsilyloxy)-4-methylocta-2,4-dienylamino)-2,4-dimethyl-7-oxohept-5-en-3-yl) 1-(2-(chloromethyl)-oxazole-4-carbonyl)pyrrolidine-2-carboxylate 
• 1025771-51-0 (R)-methyl 2-((2-chloro-5-(((1-(3-chlorophenyl)ethyl)amino)-methyl)phenoxy)methyl)oxazole-4-carboxylate 
• 916810-53-2 methyl 2-{[[4-cyano-3-(trifluoromethyl)phenyl](2,2,2-trifluoroethyl)amino]methyl}-1,3-oxazole-4-carboxylate 
• 1097777-99-5 methyl 2-{[5-({[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)-1H-indol-1-yl]methyl}-1,3-oxazole-4-carboxylate 
• 1097777-98-4 2-{[5-({[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)-1H-indol-1-yl]methyl}-1,3-oxazole-4-carboxylic acid 
• 1266100-96-2 C₂₅H₂₅ClFN₃O₄ 

Relevant articles and documents

An efficient, practical approach to the synthesis of 2,4-disubstituted thiazoles and oxazoles: Application to the synthesis of GW475151

GlaxoWellcome Research and Development, Chemical Development Division, Medicines Research Centre,. A new method for the synthesis of 2,4-disubstituted oxazoles and thiazoles and 2,4,5-trisubstituted oxazoles from readily available starting materials is described. The methodology has been applied on multigram scale and involves transfer of oxidation state through a molecular framework. In particular the oxazole-containing amino acid fragment of the 5,5-transfused lactam GW475151, 1, has been prepared in excellent yield and purity.

Facile synthesis of autophagonizer and evaluation of its activity to induce autophagic cell death in apoptosis-defective cell line

Some cancer cells are resistant to apoptosis, rendering them irresponsive towards apoptosis-inducing chemotherapy drugs. Another mode of action to kill these apoptosis-defective cells is essential and autophagy, a dynamic process that degrades cytoplasmic contents for cellular maintenance, has been considered as one of the alternate routes. A small molecule inducer of autophagy, autophagonizer was reported to induce cell death through a novel process that is independent of extrinsic apoptosis and the normal signaling pathways of autophagy. Here, we describe an efficient synthetic procedure for the autophagonizer. The newly synthesized autophagonizer (DK-1-49) resulted in an accumulation of autophagy-associated LC3-II and enhanced levels of autophagosomes and acidic vacuoles. Furthermore, cell viability was inhibited by autophagic cell death in not only human cancer cells but also Bax/Bak double-knockout cells. These findings highlight that intrinsic apoptosis is not also involved in the induction of cellular death by the autophagonizer suggesting the autophagonizer is a promising candidate for anticancer therapeutics for cancer cells that are resistant to apoptosis-inducing chemotherapy.

HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF

Heterocyclic compounds of Formula (I) and pharmaceutically acceptable salt thereof are disclosed. The use of such heterocyclic compounds and pharmaceutically acceptable salt thereof for the treatment of cancers, and more particularly cancers sensitive to mitochondrial activity inhibition and increased reactive oxygen species (ROS) levels, is also disclosed. Such cancers include acute myeloid leukemia (AML), preferably AML characterized by certain features, such as high level of expression of one or more Homeobox (HOX)-network genes, high and/or low expression of specific genes, the presence of one or more cytogenetic or molecular risk factors such as intermediate cytogenetic risk, Normal Karyotype (A/K), mutated NPM1, mutated CEBPA, mutated FLT3, mutated DNMT3A, mutated TET2, mutated IDH1, mutated IDH2, mutated RUNX1, mutated WT1, mutated SRSF2, intermediate cytogenetic risk with abnormal karyotype (intern(abnK)), trisomy 8 (+8) and/or abnormal chromosome (5/7), and/or a high leukemic stem cell (LSC) frequency.

N-[2-(2-AMINO-6,6-DISUBSTITUTED-4, 4A, 5, 6-TETRAHYDROPYRANO [3,4-D][1,3] THIAZIN-8A (8H)-YL) -1, 3-THIAZOL-4-YL] AMIDES

The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula (I), and the variables R1, R2 and R3